Particle Therapy in the Third Millennium: Current Status and Future Outlook

  • Radhe Mohan
  • Uwe Titt
  • Fada Guan


Robert Wilson’s recognition of the therapeutic potential of the physical characteristics of protons formed the foundation of particle therapy. He proposed the use of charged particles for the radiotherapy of cancers in 1946 [1]. Although the clinical promise of particle therapy was considered undisputable, there were only intermittent developments and limited adoption of this modality until the end of the twentieth century, presumably because of the high cost of establishing and operating clinical particle therapy facilities. Most of the particle treatments during that period were carried out at facilities designed for physics experiments. Notable among these facilities were Lawrence Berkeley National Lab (LBNL) (1955–1992, protons); MGH-Harvard Cyclotron (1961–2001, protons); LBNL (1975–1992, heavy ions); HIMAC, NIRS, Japan (1994–, Carbon ions); Paul Scherrer Institute (PSI), Switzerland (1996–, protons); and GSI, Germany (1997–, Carbon ions). Of these, PSI is the only facility that has employed scanning beams and intensity-modulated proton therapy (IMPT) from the inception. Loma Linda University was the first to establish a hospital-based proton therapy facility in 1990, followed by NCC, Japan, in 1998.


Dose Distribution Robust Optimization Relative Biological Effectiveness Proton Therapy Proton Beam Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Kosaki K, Ecker S, Habermehl D, Rieken S, Jakel O, Herfarth K, Debus J, Combs SE. Comparison of intensity modulated radiotherapy (IMRT) with intensity modulated particle therapy (IMPT) using fixed beams or an ion gantry for the treatment of patients with skull base meningiomas. Radiat Oncol. 2012;7:44. Scholar
  2. 2.
    Chang JY, Zhang X, Wang X, Kang Y, Riley B, Bilton S, Mohan R, Komaki R, Cox JD. Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in stage i or stage iii non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006;65:1087–96. Scholar
  3. 3.
    Frese MC, Yu VK, Stewart RD, Carlson DJ. A mechanism-based approach to predict the relative biological effectiveness of protons and carbon ions in radiation therapy. Int J Radiat Oncol Biol Phys. 2012;83:442–50. Scholar
  4. 4.
    Barendsen GW, Koot CJ, Van Kersen GR, Bewley DK, Field SB, Parnell CJ. The effect of oxygen on impairment of the proliferative capacity of human cells in culture by ionizing radiations of different let. Int J Radiat Biol Relat Stud Phys Chem Med. 1966;10:317–27. Scholar
  5. 5.
    Brada M, Pijls-Johannesma M, De Ruysscher D. Proton therapy in clinical practice: current clinical evidence. J Clin Oncol. 2007;25:965–70. Scholar
  6. 6.
    De Ruysscher D, Mark Lodge M, Jones B, Brada M, Munro A, Jefferson T, Pijls-Johannesma M. Charged particles in radiotherapy: a 5-year update of a systematic review. Radiother Oncol. 2012;103:5–7. Scholar
  7. 7.
    Allen AM, Pawlicki T, Dong L, Fourkal E, Buyyounouski M, Cengel K, Plastaras J, Bucci MK, Yock TI, Bonilla L, Price R, Harris EE, Konski AA. An evidence based review of proton beam therapy: the report of astro’s emerging technology committee. Radiother Oncol. 2012;103:8–11. Scholar
  8. 8.
    Chang JY, Komaki R, Lu C, Wen HY, Allen PK, Tsao A, Gillin M, Mohan R, Cox JD. Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage iii nonsmall cell lung cancer. Cancer. 2011;117:4707–13. Scholar
  9. 9.
    Goitein M. Calculation of the uncertainty in the dose delivered during radiation therapy. Med Phys. 1985;12:608–12. Scholar
  10. 10.
    Urie M, Goitein M, Holley WR, Chen GT. Degradation of the bragg peak due to inhomogeneities. Phys Med Biol. 1986;31:1–15. Scholar
  11. 11.
    Urie MM, Goitein M, Doppke K, Kutcher JG, LoSasso T, Mohan R, Munzenrider JE, Sontag M, Wong JW. The role of uncertainty analysis in treatment planning. Int J Radiat Oncol Biol Phys. 1991;21:91–107. Scholar
  12. 12.
    Urie M, Goitein M, Wagner M. Compensating for heterogeneities in proton radiation therapy. Phys Med Biol. 1984;29:553–66. Scholar
  13. 13.
    Britten RA, Nazaryan V, Davis LK, Klein SB, Nichiporov D, Mendonca MS, Wolanski M, Nie X, George J, Keppel C. Variations in the rbe for cell killing along the depth-dose profile of a modulated proton therapy beam. Radiat Res. 2013;179:21–8. Scholar
  14. 14.
    Robertson JB, Williams JR, Schmidt RA, Little JB, Flynn DF, Suit HD. Radiobiological studies of a high-energy modulated proton beam utilizing cultured mammalian cells. Cancer. 1975;35:1664–77. Scholar
  15. 15.
    Girdhani S, Sachs R, Hlatky L. Biological effects of proton radiation: what we know and don’t know. Radiat Res. 2013;179:257–72. Scholar
  16. 16.
    Paganetti H, Niemierko A, Ancukiewicz M, Gerweck LE, Goitein M, Loeffler JS, Suit HD. Relative biological effectiveness (rbe) values for proton beam therapy. Int J Radiat Oncol Biol Phys. 2002;53:407–21. Scholar
  17. 17.
    ICRU-78-Report-Committee. ICRU report 78, prescribing, recording, and reporting proton-beam therapy. J ICRU. 2007;7:1–210.Google Scholar
  18. 18.
    Delaney T, Kooy H. Proton and charged particle radiotherapy. Philadelphia: Lippincott Williams & Wilkins; 2008.Google Scholar
  19. 19.
    Flanz J, Smith A. Technology for proton therapy. Cancer J. 2009;15:292–7. Scholar
  20. 20.
    Cao W, Lim GJ, Lee A, Li Y, Liu W, Ronald Zhu X, Zhang X. Uncertainty incorporated beam angle optimization for IMPT treatment planning. Med Phys. 2012;39:5248–56. CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Liu W, Frank SJ, Li X, Li Y, Park PC, Dong L, Ronald Zhu X, Mohan R. Effectiveness of robust optimization in intensity-modulated proton therapy planning for head and neck cancers. Med Phys. 2013;40:051711. Scholar
  22. 22.
    Liu W, Frank SJ, Li X, Li Y, Zhu RX, Mohan R. Ptv-based IMPT optimization incorporating planning risk volumes vs robust optimization. Med Phys. 2013;40:021709. Scholar
  23. 23.
    Liu W, Li Y, Li X, Cao W, Zhang X. Influence of robust optimization in intensity-modulated proton therapy with different dose delivery techniques. Med Phys. 2012;39:3089–101. Scholar
  24. 24.
    Liu W, Zhang X, Li Y, Mohan R. Robust optimization of intensity modulated proton therapy. Med Phys. 2012;39:1079–91. Scholar
  25. 25.
    Guan F, Bronk L, Titt U, Lin SH, Mirkovic D, Kerr MD, Zhu XR, Dinh J, Sobieski M, Stephan C, Peeler CR, Taleei R, Mohan R, Grosshans DR. Spatial mapping of the biologic effectiveness of scanned particle beams: towards biologically optimized particle therapy. Sci Rep 5. 2015;9850:1–10.
  26. 26.
    Kempe J, Gudowska I, Brahme A. Depth absorbed dose and let distributions of therapeutic 1h, 4he, 7li, and 12c beams. Med Phys. 2007;34:183–92. Scholar

Copyright information

© Springer India 2016

Authors and Affiliations

  1. 1.Department of Radiation PhysicsMD Anderson Cancer CenterHoustonUSA

Personalised recommendations